R

Regeneron Pharmaceuticals

Develops biopharmaceutical therapies for serious diseases

Executive Director - Global Lung Marketing

Full-TimePosted on 10/27/2026
$255k - $424.9k/yr
Expert
Bachelor's
Sleepy Hollow, NY, USA
HybridIn the Sleepy Hollow office 4 days a week.
Growth & MarketingProduct Marketing

About the job

Requirements
  • A bachelor's degree is required at a minimum.
  • At least 15 years of progressive experience in pharmaceutical marketing, brand strategy, and execution is required.
  • Deep experience in global commercial marketing and brand positioning and strategy development for oncology projects in the United States is required.
  • Experience marketing outside the United States, with appreciation for access and commercial challenges in those markets and regions, is required.
  • Extensive experience with marketing technical skills from strategy through tactical execution, and understanding of brand management, is required.
  • A proven track record of market analysis and identifying global growth opportunities is required.
  • Understanding global-to-local market trade-offs during commercialization planning for oncology assets is required.
  • Experience leading cross-functional teams within a pharmaceutical or healthcare organization in the United States and internationally, specifically for oncology assets, is required.
  • A track record of adapting strategies based on market access, regulatory, development, and other cross-functional considerations is required.
  • A track record of creating and driving initiatives supporting global launch planning and marketing, and life cycle management strategy and planning, is required.
  • Experience leading and developing long-range brand plans, budgets, and forecasts within commercial teams in the pharmaceutical or biotechnology industry is required.
  • Strong analytical skills for tracking and communicating metrics are required.
  • The ability to communicate healthcare professional and key opinion leader engagement levels and project results to management and cross-functional partners is required.
  • Strong project and process skills, with attention to detail, are required.
  • The candidate must communicate and act promptly, demonstrate initiative and creativity, and work effectively in complex, rapidly changing environments.
  • The candidate must be proactive, able to prioritize, and comfortable leading in ambiguity.
  • Interpersonal and presentation skills, both internally and externally, and professional behaviors that support a productive team environment are required.
  • A proficient understanding of oncology provider treatment environments and economics across academic and community hospitals and clinics, buy-and-bill, specialty pharmacies, group purchasing organizations, integrated delivery networks, public health service hospitals, hospital and system pharmacies, and payers is required.
  • Understanding of the oncology therapeutic area, drug development process, and regulatory environment is required.
  • Extensive people-management experience is required.
Responsibilities
  • Lead and inspire a large, tumor-focused marketing team comprising United States and international headquarters marketers and United States field-based team members; build trust, foster learning agility, develop marketing talent, and attract leaders.
  • Establish and evolve global tumor strategy to drive differentiation and portfolio value across geographies, balancing United States and international market input.
  • Plan global and local market execution, balancing and prioritizing tactical initiatives to build and implement strategy.
  • Lead global brand planning and develop tumor-area brand and asset strategies to increase asset value.
  • Collaborate with Clinical, Medical Affairs, and Field Medical to align with medical education strategic plans.
  • Provide strategic input to the Lung Marketing Team's collaboration with Insights and Data Analytics to conduct global market analyses and translate them into strategic choices and global priorities.
  • Represent the tumor area in commercial and clinical decision-making forums to influence prioritization, resource allocation, and long-range planning based on scientific and commercial potential.
  • Collaborate with other disease-area leads to align brand activities.
  • Manage direct reports and their teams, aligning work with global strategy and vision and directing and prioritizing critical activities and initiatives.
  • Develop professional relationships with global physician experts and attend key congresses.
  • Create processes and lead initiatives for commercial launch and marketing efforts, addressing oncology commercialization hurdles where applicable.
  • Maintain visibility into global profit and loss for skin cancer products across markets and be accountable for United States profit and loss.
  • Ensure marketing processes, programs, and internal reports are developed, implemented, and administered consistently with corporate guidance and applicable regulatory, legal, and ethical guidelines.
  • Support promotional-content development and ensure the effectiveness of Medical/Legal/Regulatory Review committees.
  • Manage and develop team members, supporting their continued development and growth.
  • Ensure the team develops and tracks indicators to monitor promotional activity success and refines strategy and tactics based on outcomes.
  • Report status, future plans, and issues to the Vice President of Global Oncology Marketing and align with the vice president and senior leadership on strategic planning.
  • Support the Vice President of Global Oncology Marketing with senior-leadership reporting on the Lung business, including commercial business reviews.
  • Ensure alignment with other disease-area leads.
  • Work cross-functionally to create, manage, and track the United States and global Lung budget, ensure operations stay within approved budget and phasing, and identify efficiencies.
Desired Qualifications
  • Oncology experience is preferred; non-small cell lung cancer experience is a plus.
  • Prior pharmaceutical sales experience is preferred.

About the company

R

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops and commercializes medicines for serious diseases, with a focus on cancer, eye diseases, allergic and inflammatory diseases, and infectious diseases. Its products come from using proprietary research capabilities and technologies to discover and develop therapies, often in collaboration with academic, research, and industry partners. Revenue comes from selling approved medicines and from licensing its technologies and entering co-development and co-commercialization partnerships. The company works with healthcare providers and regulators to ensure treatment delivery and safety. Its goal is to improve patient outcomes by bringing life-transforming medicines to market through rigorous R&D and strategic collaborations, maintaining leadership in biopharmaceutical innovation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Mount Pleasant, New York

Founded

1988

Get referred to Regeneron Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi paid $1 billion upfront, with up to $7 billion more for Regeneron's immunology pipeline.
  • Q2 2026 revenue rose 17% to $4.3 billion; Dupixent sales hit $6.0 billion.
  • Libtayo and EYLEA HD both posted record sales in Q2 2026, widening diversification.

What critics are saying

  • EYLEA biosimilar competition starts in January 2027 after Samsung's settlement.
  • Regeneron faces a 2026 SDNY securities class action over the failed fianlimab melanoma trial.
  • Dupixent's patent cliff later this decade threatens the company's biggest profit pool.

What makes Regeneron Pharmaceuticals unique

  • VelocImmune keeps generating partnered immunology assets; Sanofi renewed the alliance on October 1, 2026.
  • Dupixent remains Regeneron's engine, with over 1.5 million patients across nine indications.
  • EYLEA HD conversion shows platform strength; U.S. sales hit $596 million in Q2 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Wellness Program
  • Paid Vacation
  • Equity Awards
  • Annual Bonuses
  • Flexible Work Hours

Growth & Insights and Company News

6 month growth

1%

1 year growth

12%

2 year growth

12%
Yahoo Finance
Oct 26th, 2026
Regeneron to book full Dupixent profit share in Q3 after $930M repayment drag

Regeneron reports third-quarter results on October 30, and it will book its full share of Dupixent profits from Sanofi for the first time. Repayments of a development balance, which stood at about $3.1 billion in 2022, cut collaboration revenue by roughly $930 million in 2025. Last quarter, Regeneron posted non-GAAP earnings per share of $14.29 against an $8.00 consensus. Revenue rose 16.73% to $4.29 billion, and global Dupixent sales reached $6.00 billion, up 38%. The companies also expanded their alliance to up to $8 billion, adding four long-acting antibodies and settling prior litigation. Eylea HD US sales hit $596 million, up 52%, passing legacy Eylea for the first time. Analysts expect third-quarter revenue of $4.56 billion.

Yahoo Finance
Oct 21st, 2026
Regeneron trades at 19.2x earnings versus Amgen's 27.1x despite similar growth

Regeneron Pharmaceuticals trades at 19.2 times earnings for the four quarters ended June 30, 2026, well below Amgen's 27.1, though both grew revenue at a similar pace. Regeneron's revenue rose 9.3% against Amgen's 9.1%. Amgen has the higher operating margin, at 30.0% against 26.9%. Its shares also gained more over the past year, rising 51.0% against 40.4%. Regeneron's largest drug, EYLEA, is shrinking. Its revenue fell to $2.75 billion in fiscal 2025 from $4.77 billion, and management expects demand to fall further as biosimilars launch. Partners supply about half of revenue, and management expects Sanofi collaboration revenue to rise from fiscal Q3 2026. The next report is expected on or around October 30, 2026.

Yahoo Finance
Oct 19th, 2026
Regeneron's weight loss drugs could challenge Eli Lilly and Novo with 19% weight loss

Regeneron Pharmaceuticals could carve out a place in the fast-growing weight loss market, where Eli Lilly and Novo are expected to stay ahead for about five years. Its drug olatorepatide, licensed from a China-based company, mimics the GLP-1 and GIP hormones, as Lilly's Zepbound does. In a Phase 3 study in China, it led to mean weight loss of up to 19% over 48 weeks, with fewer stomach-related side effects than some rivals. Regeneron still needs US late-stage trials before approval. Its other candidate, trevogrumab, helps patients keep lean mass. In a Phase 2 study alongside Novo's semaglutide, lean mass preservation reached up to 42.5%, against 7.3% with semaglutide plus placebo. Second-quarter revenue rose 17% year over year to $4.3 billion, driven by eczema drug Dupixent.

Yahoo Finance
Oct 14th, 2026
Regeneron's Sanofi repayment ends, setting up a possible revenue boost after $2.2B record quarter

Regeneron Pharmaceuticals may get its next boost from an old deal rather than a new drug. The company finished repaying a balance to its partner Sanofi, and since the third quarter of 2026 it has recorded its full share of profits from their collaboration. Regeneron expects Sanofi collaboration revenue to step up as a result, though that remains a forecast. The repayment cut reported revenue by about $930 million in 2025 and $530 million in the first half of 2026. Revenue from the collaboration already hit a record $2.2 billion in the second quarter. A step-up matching the 2025 loss would add about 6.5% to the company's 2025 revenue of $14.3 billion. Dupixent sales reached $6 billion worldwide in the quarter, up 38% at constant currency, but growth should moderate in the second half.

Asianet News
Oct 13th, 2026
Regeneron's rare disease drug shows zero new abnormal bone growth in extended trial - REGN stock heads for best day in over A month.

Regeneron's rare disease drug shows zero new abnormal bone growth in extended trial - REGN stock heads for best day in over A month. Published: Oct 13 2026, 12:15 AM IST * FB * TW * Linkdin * Whatsapp * GNFollow Us The firm's Pasatru drug was approved by the FDA in August, after trial results showed at least a 90% reduction in new abnormal bone lesions after 56 weeks. * The Phase 3 Optima trial enrolled 63 adults who received Pasatru or a placebo every four weeks. * A higher dose recorded one disease flare-up, compared with 17 in the placebo group. * The findings were presented at the American Society for Bone and Mineral Research. Regeneron Pharmaceuticals (REGN) reported encouraging long-term results for its recently approved rare disease drug on Monday, with patients showing no new abnormal bone growth during an extended Phase 3 trial. REGN shares were up about 2.8% and heading for their best day in over a month. What did the trial show? Regeneron's Pasatru treats fibrodysplasia ossificans progressiva (FOP), an extremely rare condition in which muscles, tendons and other soft tissues gradually turn into bone. The Phase 3 Optima trial enrolled 63 adults who received Pasatru or a placebo every four weeks. Between weeks 56 and 84, patients taking Pasatru developed zero new abnormal bone lesions, compared with nine in the placebo group. The findings were presented at the American Society for Bone and Mineral Research (ASBMR). Regeneron plans new study for children. The FDA approved Pasatru in August, following earlier trial results showing at least a 90% reduction in new abnormal bone lesions after 56 weeks. European regulators are currently reviewing Pasatru. The drug works by blocking Activin A, a protein involved in abnormal bone formation. Regeneron plans to begin another Phase 3 study, Optima 2, involving children and adolescents later this year. REGN's pipeline includes cancer, eye disease treatments. Beyond Pasatru, Regeneron is expanding its broader drug pipeline, which includes treatments for cancer, eye diseases and inflammatory conditions. The biotech firm recently expanded its partnership with Sanofi (SNY) to develop four new long-acting antibody treatments for inflammatory diseases. Under the deal, Regeneron will receive $1 billion upfront and could earn an additional $7 billion if the treatments meet certain development, regulatory, and sales targets. The companies will share development costs and split future profits equally. The company reported about $17.8 billion in cash and marketable securities as of June 30. Separately, BofA raised its price target on Regeneron to $908 from $891 and kept a 'Buy' rating. This implies a 19% upside from current levels. Retail remains bullish on REGN. Despite the recent run, retail sentiment on Stocktwits surrounding REGN remained 'bullish' over the past 24 hours. The stock is down around 1.4% so far this year, underperforming the broader State Street SPDR S&P Biotech ETF's (XBI) roughly 25% gains. Also read: Microsoft Looks In-House To Power Its AI Ambitions - CEO Nadella Calls It 'Our Biggest Bet Yet On Our Own Silicon' For updates and corrections, email newsroom[at]stocktwits[dot]com.< Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business. 0 Comments / 0 New